Allergan makes major urology acquisition
This article was originally published in Scrip
Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
You may also be interested in...
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.